Fatal acute pulmonary fibrosis in a patient treated by danazol for thrombocytopenia

Marie‐José Grange, Marie-Christine Dombret, Marie‐Christine Dombret, B. Fantin, Marie‐Anne Gougerot‐Pocidalo
In: American Journal of Hematology · 1996 · vol. 53(2) , pp. 149 · doi:10.1002/(sici)1096-8652(199610)53:2<149::aid-ajh22>3.3.co;2-l · W4245094087
article OA: bronze CC0 ⤵ 1 in-corpus citation
🔓 Open OA copy View on OpenAlex View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-08-14 ⓘ

The provided text contains a mismatch between the title regarding danazol and pulmonary fibrosis, and an abstract discussing beta-2 microglobulin levels in lymphoid malignancies like CLL and PLL, making it impossible to summarize the paper's findings on endometriosis or adenomyosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

has prognostic value in lymphoid malignancies such as multiple myeloma and CLL. High P2m values in CLL have been found to correlate mainly with stage of disease and high lymphocyte count 131. Prolymphocytic leukemia is a disease of activated B lymphocytes more differentiated than B-CLL cells. PLL cells express B cell activation antigens CD25, CD38, CD71, FMC7, PCAl, and RABl 141. We found a significantly higher level of p2m in PLL than in CLL patients. Our results indicate that P2m levels may be an additional marker of B-cell activation to further characterize lymphoid diseases arrested in different stages of maturation.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (1)

References (2)

Cited by (1)

Source provenance

openalex
last seen: 2026-05-10T10:43:42.427797+00:00
License: CC0 · commercial use OK